# Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)

> **NCT03236688** · — · SUSPENDED · sponsor: **Exosome Diagnostics, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03236688
- **Lead sponsor:** Exosome Diagnostics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2016-02
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236688, "Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03236688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*